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Lysidine (k2C) is one of the most modified pyrimidine RNA bases. It is a cytidine nucleoside, in which the 2-
oxo functionality of the heterocycle is replaced by the ɛ-amino group of the amino acid lysine. As such, lysidine
is an amino acid-containing RNA nucleoside that combines directly genotype (C-base) with phenotype (lysine
amino acid). This makes the compound particularly important in the context of theories about the origin of life
and here especially for theories that target the origin of translation. Here, we report the total synthesis of the U-
derivative of lysidine (k2U), which should have the same base pairing characteristics as k2C if it exists in the isoC-
like tautomeric form. To investigate this question, we developed a phosphoramidite building block for k2U,
which allows its incorporation into RNA strands. Within RNA, k2U can base pair with the counter base U and isoG,
confirming that k2U prefers an isoC-like tautomeric structure that is also known to dominate for k2C. The
successful synthesis of a k2U phosphoramidite and its use for RNA synthesis now paves the way for the
preparation of a k2C phosphoramidite and RNA strands containing k2C.
Keywords: lysidine, modified RNA bases, RNA, nucleosides, origin of life, prebiotic chemistry.
Introduction
RNA contains a vast variety of modified nucleosides.[1]
Many of the modified bases are just methylated
versions of the canonical nucleosides A, C, G and U,
but other are highly modified. This is achieved with
the help of dedicated biosynthesis machineries.[2]
From a prebiotic point of view in which genotype-
phenotype discussions address the question of
whether life started with nucleic acids or peptides, the
most interesting modified nucleosides are those which
are modified with amino acids.[3] These molecules are
chemical structures between genotype and pheno-
type. They directly merge the properties of nucleic
acids with those of amino acids. As such, RNA
containing these amino acid-modified bases could
have been a central element for the origin of life and
for the origin of translation as already discussed by
Grosjean and others.[4–7] RNA containing these amino
acids could establish catalytic properties next to
information encoding functions. Catalytic RNAs in turn
are the central elements in all discussions about how
life emerged from simple starting materials.[8,9]
One of the most interesting amino acid modified
nucleosides is lysidine (k2C),[10,11] which is a cytidine
base to which a lysine amino acid is attached with the
ɛ-amino group to the C(2) position (Figure 1). Agmati-
dine (agm2C)[12,13] is a close relative, which features the
guanidinium group found in the amino acid arginine
(Figure 1). We also want to mention the amino acid
modified RNA base puromycin in which the amino
acid is attached to the C(3’)-OH group. This base is in
use for ribosomal studies.[14,15] In our effort to
investigate the properties of RNA containing amino
acid-modified nucleosides as units that equip such
RNA potentially with peptide-like properties, we were
interested to study the lysine modified uridine base.
This compound is a close derivative of lysidine, which
we name k2U. k2U is in principle the deamination
product of k2C which has likely occurred under
prebiotic conditions, where the bases were exposed to
potentially hot aqueous environments.[16,17] Under
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these conditions, deamination of k2C to k2U is an
expected process. k2U can in principle exist is two
tautomeric states. In one it has U-type base pairing
properties, while in the second it should behave like
an isoC similar to k2C, which also exists in a quinoid-
like tautomeric structure (Figure 1)[10,18–23]. In this latter
scenario, k2U and k2C are supposed to have similar
base pairing properties. A major difference could be
that while k2C is protonated, k2U is likely not. k2C
protonation is supposed to occur at N(6) and hence it
does not change the base pairing properties.[10,24]
Results and Discussion
To investigate how k2U is affecting the structure and
properties of RNA, we started the synthesis of k2U as
its phosphoramidite building block (k2U-PA) and
investigated procedures that allow its incorporation
into RNA. The synthesis of the k2U-PA is depicted in
Scheme 1. The synthesis was started with carboxyben-
zoyl- (Cbz) protected lysine 1, which we converted
with 1-({[2-(trimethylsilyl)ethoxy]carbonyl}oxy)pyrroli-
dine-2,5-dione into the Cbz- and Teoc-protected lysine
compound 2. Subsequent protection of the carboxy
group with 2-(trimethylsilyl)ethanol furnished the fully
protected lysine amino acid 3. After Cbz-deprotection,
we obtained the amino acid coupling partner 4. At the
nucleoside side, we treated uridine 5 under Mitsunobu
conditions with DIAD and PPh3 to obtain the liter-
ature-known 2’,3’-protected cyclouridine compound
6.[25] Coupling of this intermediate with the lysine
building block 4 in the presence of LiCl and DBU
furnished the protected lysine coupled uridine deriva-
tive 7. We next protected the primary 5’-OH group
with DMTCl and the secondary 2’-OH group with TBSCl
to give the intermediate 9.[26–28] Compound 9 was
finally converted into the phosphoramidite building
block using a standard procedure.[29] Purification of
the k2U-PA was difficult due to its high polarity. We
needed to use a rather polar mixture of dichloro-
methane/acetone (8 : 3) as the mobile phase for the
chromatographic purification. This provided, however,
the target compound k2U-PA in a total yield of 12% in
just eight steps in a good but not excellent purity.
To study the properties of k2U in RNA, we next
inserted the compound into an RNA strand using solid
phase RNA synthesis.[30–33] The oligonucleotide syn-
thesis was performed using standard coupling con-
ditions. This allowed us to achieve a coupling yield of
30%. Importantly, the incorporation of the next canon-
ical bases, e.g., coupling of uridine to k2U, was not
affected. We achieved elongation yields that reached
typically 95–98%. All together the method provided
enough material for all further studies. Optimization of
the k2U-incorporation yield was consequently not
performed. In addition, we noted that the purity of the
obtained strands was high allowing rapid separation
of the target k2U containing oligonucleotide. After the
RNA synthesis, we removed the Teoc- and TMSE-
protecting groups from the lysine moiety with satu-
rated ZnBr2 solution in isopropanol/nitromethane
(1 :1) at r.t. over night. It is interesting that the RNA
strand is stable under these quite Lewis acidic
conditions. Our observation, however, agrees with an
earlier report.[34] Own attempts to cleave the Teoc-
and TMSE-protecting groups with HF·Et3N complex
provided only partial deprotection which gave a
mixture of products. In our hands, the reported ZnBr2
method gave superior results.[33] RNA degradation was
not observed.
We subsequently cleaved the oligonucleotide from
the solid support and removed the protecting groups
from the canonical bases with a mixture of meth-
ylamine and ammonia (1 :1) at 65 °C for 5 min. Figure 2
shows the sequence of the prepared oligonucleotide
together with the raw HPL-chromatogram and the
MALDI-TOF spectrum. These data prove the integrity
Figure 1. Depiction of agmatidine (agm2C), lysidine (k2C) and of
the potential prebiotically relevant deamination product (k2U)
of k2C.
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and the high purity of the synthesized k2U-containing
RNA strand.
We finally studied how the k2U base affects the
stability of the RNA duplex. Figure 3 shows the melting
curves of the k2U-containing oligonucleotide (k2U:A
base pair, red) in comparison to the unmodified RNA
duplex containing a U :A base pair (black). The table in
Figure 3 depicts all melting points measured for k2U
facing any of the four canonical bases, together with
all possible combinations of canonical bases as
reference strands. While the U :A reference strand
melts at 42 °C, replacement of U by k2U reduces the
melting temperature (k2U:A) to just 32 °C, which is a
dramatic destabilization. This is unexpected and not
explainable with a U-type tautomeric structure, be-
cause the lysine residue can in principle point out of
the large shallow groove of the RNA-duplex in A-
Scheme 1. Synthesis of k2U and of its phosphoramidite building block k2U-PA.
Figure 2. a) Sequence of the k2U-containing RNA strand
together with the raw-HPL chromatogram of ON1. The inset
shows the HPL-chromatogram of the purified ON1. b) MALDI-
TOF mass spectrum of ON1 after purification.
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conformation. Because the C(2)-O atom, which is
replaced by the lysine residue, does not take part in
the H-bonding to the A-counterbase as depicted in
Figure 1, the lysine residue should not affect base
pairing so strongly if k2U would exist in the U-
tautomeric form. Further melting point studies in
which we exchanged systematically the counter base
showed the k2U is unable to undergo any productive
base pairing. The only slight stabilization that we
detected is in the k2U:U situation (38 °C), which is
compared to the U :U (34 °C) situation stabilized by
4 °C.
This rather large global destabilization is best
explained, if we assume that the k2U base exists
indeed not in the typical U-tautomer but in the
hemiquinoid tautomeric state known from isoC (Fig-
ure 4). As such, k2U behaves like an isoC tautomer,
which indeed prohibits k2U to form productive base
pairs with any of the other canonical bases particularly
with the purine bases A and G. The slight interaction
with U is in this scenario explained because the U
counterbase can get engaged with isoC-tautomeric
k2U with two H-bonds. To investigate this isoC type
structure of k2U in more detail, we created a duplex in
which k2U is facing isoG as the counterbase. Indeed, in
this situation we measure a higher melting point of
37 °C (Figure 4) close to the k2U:U situation (38 °C), in
fully agreement with the idea that k2U is a lysine
modified isoC derivative that has an k2C like tauto-
meric structure. Further support for the idea that the
k2U base exists predominantly in the quinoid tauto-
meric structure comes from NMR data. In our com-
pounds with the k2U base the typical NH 1H-NMR
signal around δ=9.5 ppm was not observed. Instead
we observed the NH signal at around δ=7.0 ppm, in
line with the quinoid tautomeric structure of k2U
(Figure 4). This shift to around δ=7.0 ppm agrees with
literature data about such compounds.[35]
Conclusions
Here, we report the development of a phosphorami-
dite building block of k2U which is a close deami-
nation-based relative of the non-canonical base k2C.
We show that the modified base can be incorporated
into RNA strands using standard phosphoramidite
chemistry in combination with a three-stage depro-
tection protocol, in which we first cleave the protect-
ing groups at the lysine residue, followed by depro-
tection of the nucleobases and cleavage from the
resin. Melting point studies and NMR data show that
k2U exists in a tautomeric state that resembles the
situation in isoC. As such, k2U destabilizes RNA
duplexes dramatically allowing only limited interac-
tions with U and most importantly isoG as counter-
bases.
Experimental Section
General Methods
Chemicals were purchased from Sigma–Aldrich, TCI,
Fluka, ABCR, Carbosynth or Acros organics and used
without further purification. Strands containing canon-
ical bases and isoG were purchased from Metabion.
The solvents were of reagent grade or purified by
distillation, unless otherwise specified. Reactions and
chromatography fractions were monitored by qualita-
tive thin-layer chromatography (TLC) on silica gel F254
TLC plates from Merck KGaA. Flash chromatography
was performed on Geduran® Si60 (40–63 μm) silica gel
from Merck KGaA. NMR spectra were recorded on
Bruker AVIIIHD 400 spectrometers (400 MHz). 1H-NMR
shifts were calibrated to the residual solvent resonan-
Figure 3. a) Depiction of melting curve with the duplex
containing U :A base pair (black), and k2U:A (red); b) table of all
melting points measured for k2U.
Figure 4. a) Depiction of melting curve with the duplex
containing k2U:isoG base pair; b) depiction of base pairing of
isoC:isoG and k2U:isoG.
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ces: (D6)DMSO (2.50 ppm), CDCl3 (7.26 ppm), (D6)
acetone (2.05 ppm). 13C-NMR shifts were calibrated to
the residual solvent: (D6)DMSO (39.52 ppm), CDCl3
(77.16 ppm), (D6)acetone (29.84 ppm). All NMR spectra
were analyzed using MestRENOVA 10.01.1 from Mes-
trelab Research S. L. High resolution mass spectra were
measured on the spectrometer MAT 90 (ESI) from
Thermo Finnigan GmbH. Analytical RP-HPLC was
performed on an analytical HPLC Waters Alliance (2695
Separation Module, 2996 Photodiode Array Detector)
equipped with the column Nucleosil 120–2C18 from
Macherey Nagel using a flow of 0.5 ml/min, a gradient
of 0–30% of buffer B in 45 min was applied.
Preparative RP-HPLC was performed on a HPLC Waters
Breeze (2487 Dual λ Array Detector, 1525 Binary HPLC
Pump) equipped with the column VP 250/32C18 from
Macherey Nagel using a flow of 5 ml/min, a gradient of
0–25% of buffer B in 45 min was applied for the
purifications. Oligonucleotides were purified using the
following buffer system: buffer A: 100 mM NEt3/AcOH
(pH 7.0) in H2O and buffer B: 100 mM NEt3/AcOH in
80% (v/v) acetonitrile. The pH values of buffers were
adjusted using a MP 220 pH-meter (Metter Toledo).
Oligonucleotides were detected at wavelength:
260 nm. Melting profiles were measured on a JASCO V-
650 spectrometer. Calculation of concentrations was
assisted using the software OligoAnalyzer 3.0. For
strands containing artificial bases, the extinction
coefficient of their corresponding canonical-only
strand was employed without corrections. Matrix-
assisted laser desorption/ionization-time-of-flight
(MALDI-TOF) mass spectra were recorded on a Bruker
Autoflex II. For MALDI-TOF measurements, the samples
were desalted on a 0.025 μm VSWP filter (Millipore)
against ddH2O and co-crystallized in a 3-hydroxypico-
linic acid matrix (HPA).
N6-[(Benzyloxy)carbonyl]-N2-{[2-(trimethylsilyl)-
ethoxy]carbonyl}lysine (2). The reaction was per-
formed according to the published procedure.[36]
To a stirred suspension of cbz-protected lysine (1)
(3 g, 10.7 mmol, 1 equiv.) in dioxane/water (1 :1)
mixture, TEA (2.23 ml, 16 mmol, 1.5 equiv.) was added.
To the resultant solution, Teoc  OSu (3.2 g, 12.3 mmol,
1.1 equiv.) was added and the mixture was left to stir
overnight at room temperature. Afterwards, the
mixture was diluted with water, acidified with satu-
rated KHSO4 solution and extracted with diethyl ether.
The combined organic layers were washed with water,
dried over Na2SO4 and evaporated in vacuo. Yield:
85%. 1H-NMR (400 MHz, CDCl3): 7.35–7.33 (m, 5 H);
5.50–5.45 (m, 1 H); 5.09 (s, 2 H); 4.41–4.32 (m, 1 H);
4.15 (t, J=8.4, 2 H); 3.22–3.13 (m, 2 H); 1.86–1.72 (m, 2
H); 1.51–1.40 (m, 4 H); 0.97 (t, J=8.4, 2 H); 0.02 (s, 9 H).
13C-NMR (101 MHz, CDCl3): 176.4; 168.9; 156.8; 136.6;
128.6; 128.4; 128.3; 66.9; 63.7; 53.5; 40.6; 31.9; 29.5;
22.3; 17.7;   1.4. HR-ESI-MS: 425.2103 (C20H33N2O6Si
+,
[M+H]+; calc. 425.2108).
2-(Trimethylsilyl)ethyl N6-[(benzyloxy)carbonyl]-
N2-{[2-(trimethylsilyl)ethoxy]carbonyl}lysinate (3).
To the stirred solution of compound 2 (1.2 g,
2.82 mmol, 1 equiv.) in CH2Cl2/DMF (1 :1) mixture,
HBTU (1.61 g, 4.2 mmol, 1.5 equiv.), TEA (0.788 ml,
5.65 mmol, 2 equiv.) and DMAP (0.034 g, 0.27 mmol,
0.1 equiv.) were added. Then, 2-(trimethylsilyl)ethanol
(0.486 ml, 4.2 mmol, 1.2 equiv.) was added and the
mixture was left to stir overnight at room temperature.
Then, CH2Cl2 was evaporated and product was
extracted with diethyl ether and washed with water.
The organic phase was dried and evaporated. The
residue was purified by flash chromatography eluting
with hexane/AcOEt (4 : 1). Yield: 80%. 1H-NMR
(400 MHz, CDCl3): 7.35–7.30 (m, 5 H); 5.19 (d, J=8, 1
H); 5.08 (s, 2 H); 4.81 (br. s, 1 H); 4.32–4.26 (m, 1 H);
4.24–4.18 (m, 2 H); 4.14 (t, J=9, 2 H); 3.18 (q, J=6.6, 2
H); 1.82–1.62 (m, 2 H); 1.55–1.50 (m, 2 H); 1.42–1.34
(m, 2 H); 1.00–0.96 (m, 4 H); 0.04 (s, 9 H); 0.02 (s, 9 H).
13C-NMR (101 MHz, CDCl3): 172.8; 156.6; 156.4; 136.7;
128.6; 128.4; 128.2; 66.7; 63.9; 63.5; 53.7; 40.7; 32.4;
29.5; 22.4; 17.8; 17.5;   1.36;   1.39. HR-ESI-MS:
525.2817 (C25H45N2O6Si2
+, [M+H]+; calc. 525.2816).
2-(Trimethylsilyl)ethyl N2-{[2-(trimethylsilyl)eth-
oxy]carbonyl}lysinate (4). Cbz-protected lysine deriv-
ative 3 (0.7 g, 1.33 mmol, 1 equiv.) was dissolved in
methanol. Pd/C (0.096 g) was added, and the mixture
was stirred at room temperature under H2 at atmos-
pheric pressure. After 2 h, the mixture was filtered
through Celite and evaporated. Yield: 94%. 1H-NMR
(400 MHz, CDCl3): 5.18 (d, J=8, 1 H); 4.33–4.26 (m, 1
H); 4.23–4.18 (m, 2 H); 4.14 (t, J=8.5, 2 H); 2.69 (br. s, 2
H); 1.80–1.34 (m, 6 H); 0.98 (q, J=8.5, 4 H); 0.04 (s, 9
H); 0.03 (s, 9 H). 13C-NMR (101 MHz, CDCl3): 172.9;
156.4; 64.0; 63.4; 53.8; 42.2; 32.6; 28.1; 22.6; 17.8; 17.4;
  1.37;   1.40. HR-ESI-MS: 391.2444 (C17H39N2O4Si2
+,
[M+H]+; calc. 391.2448).
2’,3’-O-(Triphenylphosphoranediyl)-O2,5’-cyclo-
uridine (= (3aR,4R,12R,12aR)-2,2,2-Triphenyl-4,5,
12,12a-tetrahydro-2H,3aH,8H-4,12-epoxy-2λ5-[1,3,
2]dioxaphospholo[4,5-e]pyrimido[2,1-b][1,3]-oxaz-
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ocin-8-one; 6). The reaction was performed according
to the published procedure.[25]
To a stirred solution of uridine 5 (5 g, 20.5 mmol,
1 equiv.) in THF, PPh3 (16.1 g, 61.4 mmol, 3 equiv.) was
added. Then DIAD (12.1 ml, 61.4 mmol, 3 equiv.) was
added dropwise, and the reaction was left to stir at
room temperature overnight. Afterwards the precip-
itate was filtered, washed with THF and water, and
then dried. Yield: 64%. 1H-NMR (400 MHz, (D6)DMSO):
8.05 (d, J=7.5, 1 H); 7.67–7.51 (m, 2 H); 7.47–7.17 (15
H); 5.96–5.85 (m, 2 H); 4.84 (dd, J=6.6, 13.2, 1 H); 4.73
(s, 1 H); 4.60–4.46 (m, 2 H); 4.16 (d, J=12.7, 1 H). 13C-
NMR (101 MHz, (D6)DMSO): 170.7; 157.0; 144.8; 143.6;
130.8; 128.5; 127.6; 109.0; 97.8; 85.4; 76.8; 74.4; 72.7.
HR-ESI-MS: 487.1412 (C27H24N2O5P
+, [M+H]+; calc.
487.1423).
2-(Trimethylsilyl)ethyl N6-(4-oxo-1-pentofurano-
syl-1,4-dihydropyrimidin-2-yl)-N2-{[2-(trimeth-
ylsilyl)ethoxy]carbonyl}lysinate (7). To the dry LiCl
(0.043 g, 1.02 mmol, 5 equiv.) THF was poured fol-
lowed by the addition of DBU (0.156 g, 1.02 mmol,
5 equiv.) and amine 4 (0.16 g, 0.41 mmol, 2 equiv.).
Then, cyclouridine derivative 6 (0.1 g, 0.2 mmol,
1 equiv.) was added, and the mixture was left to stir
for 2 h at room temperature. In time, the solution
became pink and clear. Afterwards, the mixture was
evaporated, and the residue was purified by flash
chromatography eluting with MeCN/H2O (95 :5, v/v).
Yield: 88%. 1H-NMR (400 MHz, (D6)DMSO): 7.82 (s, 1 H);
7.58 (d, J=7.7, 1 H); 7.44 (dd, J=7.7, 4.6, 1 H); 7.12 (t,
J=5.2, 1 H); 5.53 (d, J=7.7, 1 H); 5.50 (d, J=7.0, 1 H);
5.44 (t, J=4.6, 1 H); 5.39 (d, J=7.0, 1 H); 5.29 (d, J=4.3,
1 H); 4.16–4.08 (m, 4 H); 4.04–3.97 (m, 4 H); 3.20 (q, J=
6.7, 2 H); 2.74 (t, J=7.6, 1 H); 1.66–1.43 (m, 4 H); 1.37–
1.26 (m, 2 H); 0.95–0.89 (m, 4 H); 0.02 (s, 18 H). 13C-
NMR (101 MHz, (D6)DMSO): 172.7; 163.5; 156.5; 150.9;
140.9; 101.9; 87.7; 73.7; 70.0; 62.7; 62.0; 60.9; 53.9; 51.9;
30.8; 30.1; 26.7; 22.6; 17.5; 16.9;   1.32;   1.35. HR-ESI-
MS: 617.3028 (C26H49N4O9Si2
+, [M+H]+; calc.
617.3038).
2-(Trimethylsilyl)ethyl N6-(1-{5-O-[bis(4-meth-
oxyphenyl)(phenyl)methyl]pentofuranosyl}-4-oxo-
1,4-dihydropyrimidin-2-yl)-N2-{[2-(trimethylsilyl)-
ethoxy]carbonyl}lysinate (8). To the solution of
nucleoside 7 (0.45 g, 0.73 mmol, 1 equiv.) in dry
pyridine, DMTCl (0.37 g, 1.1 mmol, 1.5 equiv.) was
added. The mixture was left to stir overnight at room
temperature. The product was extracted with AcOEt
and washed with sat. NaHCO3 solution. The combined
organic layers were evaporated, and the residue was
purified by flash chromatography eluting with CH2Cl2/
MeOH (10 :1, v/v) containing 0.02% of pyridine. Yield:
67%. 1H-NMR (400 MHz, (D6)acetone): 7.86 (d, J=7.8, 1
H); 7.49–7.44 (m, 2 H); 7.38–7.20 (m, 8 H); 7.02 (t, J=
5.3, 1 H); 6.92–6.87 (m, 4 H); 6.48 (d, J=8.2, 1 H); 5.71
(d, J=4.3, 1 H); 5.57 (d, J=7.7, 1 H); 4.69 (br. s, 1 H);
4.49–4.47 (m, 1 H); 4.43–4.41 (m, 1 H); 4.23 (q, J=3.5,
1 H); 4.18–4.04 (m, 5 H); 3.77 (s, 6 H); 3.47 (d, J=3.5, 2
H); 3.41–3.30 (m, 2 H); 1.83–1.52 (m, 4 H); 1.48–1.38
(m, 2 H); 1.00–0.92 (m, 4 H); 0.03 (s, 9 H); 0.02 (s, 9 H).
13C-NMR (101 MHz, (D6)acetone): 173.4; 172.2; 159.7;
157.3; 154.3; 145.7; 139.1; 136.4; 136.2; 131.0; 128.9;
128.7; 127.7; 114.0; 106.4; 92.1; 87.5; 85.4; 75.5; 71.2;
63.6; 63.1; 55.6; 55.1; 41.9; 32.2; 23.9; 18.3; 17.9;   1.3;
  1.4. HR-ESI-MS: 919.4326 (C47H67N4O11Si2
+, [M+H]+;
calc. 919.4345).
2-(Trimethylsilyl)ethyl N6-(1-{5-O-[bis(4-meth-
oxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimeth-
yl)silyl]pentofuranosyl}-4-oxo-1,4-dihydropyrimi-
din-2-yl)-N2-{[2-(trimethylsilyl)ethoxy]carbonyl}lysi-
nate (9). DMT-protected nucleoside 8 (0.1 g, 0.1 mmol,
1 equiv.) was dissolved in pyridine. Then, imidazole
(0.022 g, 0.3 mmol, 3 equiv.) and TBSCl (0.049 g,
0.3 mmol, 3 equiv.) were added. The mixture was left
to stir overnight at room temperature. Then, the
mixture was poured into saturated NaHCO3 solution
and extracted with CH2Cl2. Organic layers were
evaporated, and the residue was purified by flash
chromatography eluting with CH2Cl2/acetone (8 : 3, v/v)
containing 0.02% of pyridine. Yield: 46%. 1H-NMR
(400 MHz, (D6)acetone): 7.49–7.44 (m, 2 H); 7.38–7.29
(m, 9 H); 6.91 (d, J=8.9, 5 H); 5.67 (d, J=5.3, 1 H); 5.53
(d, J=7.7, 1 H); 4.45 (t, J=5.3, 1 H); 4.41–4.35 (m, 1 H);
4.21–4.14 (m, 4 H); 4.13–4.06 (m, 4 H); 3.79 (s, 6 H);
3.55 (dd, J=11.0, 3.0, 1 H); 3.38 (dd, J=11.0, 3.0, 1 H);
3.31 (t, J=6.7, 2 H); 1.81–1.67 (m, 2 H); 1.65–1.50 (m, 2
H); 1.47–1.34 (m, 2 H); 1.02–0.95 (m, 2 H); 0.86 (s, 9 H);
0.11 (s, 3 H); 0.05 (s, 9 H); 0.03 (s, 9 H). 13C-NMR
(101 MHz, (D6)acetone): 173.4; 170.9; 159.7; 157.2;
154.3; 145.6; 138.9; 136.2; 136.1; 131.0; 128.9; 128.7;
127.8; 114.0; 107.8; 91.4; 87.7; 85.9; 75.9; 71.7; 64.2;
63.5; 63.0; 55.5; 55.1; 41.9; 32.2; 26.1; 24.1; 18.7; 18.3;
17.9;   1.37;   1.41;   4.5;   4.7. HR-ESI-MS: 1033.5205
(C53H81N4O11Si3
+, [M+H]+; calc. 1033.5210).
2-(Trimethylsilyl)ethyl N6-[1-(5-O-[bis(4-meth-
oxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimeth-
yl)silyl]-3-O-{(2-cyanoethoxy)[di(propan-2-yl)ami-
no]phosphanyl}pentofuranosyl)-4-oxo-1,4-dihydro-
pyrimidin-2-yl]-N2-{[2-(trimethylsilyl)ethoxy]car-
Helv. Chim. Acta 2020, 103, e2000016
www.helv.wiley.com (6 of 8) e2000016 © 2020 The Authors. Helvetica Chimica Acta Published by Wiley-VHCA AG
bonyl}lysinate (k2U-PA). Compound 9 (0.1 g,
0.09 mmol, 1 equiv.) was co-evaporated three times in
dry pyridine. Then, the compound was dissolved in dry
THF and cooled to 0 °C. DIPEA (67 μl, 0.39 mmol,
4 equiv.) and 2-cyanoethyl-N,N-diisopropyl chlorophos-
phoramidite (54 μl, 0.24 mmol, 2.5 equiv.) were added
under nitrogen atmosphere. The mixture was brought
to room temperature and stirred for 2.5 h. Then, the
reaction was quenched by the addition of saturated
NaHCO3 solution and extracted with CH2Cl2. The
combined organic layers were dried and concentrated.
The residue was purified by flash chromatography
eluting with CH2Cl2/acetone (8 : 3, v/v) containing 0.3%
of pyridine. Yield: 68%. 31P-NMR (162 MHz, (D6)ace-
tone): 149.9; 148.6. HR-ESI-MS: 1233.6278
(C62H98N6O12PSi3
+, [M+H]+; calc. 1233.6288).
Synthesis and Purification of Oligonucleotide
The oligonucleotide was synthesized on a 1 μmol scale
using a DNA automated synthesizer (Applied Biosys-
tems 394 DNA/RNA Synthesizer) with standard phos-
phoramidite chemistry. The phosphoramidites of can-
onical ribonucleotides were purchased from Glen
Research and Sigma-Aldrich. Oligonucleotide contain-
ing k2U nucleoside was synthesized in DMT-OFF mode
using phosphoramidites (Bz  A, Dmf-G, Ac  C, U) with
BTT in MeCN as an activator, DCA in CH2Cl2 as a
deblocking solution and Ac2O in pyridine/THF as a
capping reagent. After the synthesis the solid support
was treated with saturated solution of ZnBr2 in
iPrOH/
MeNO2 (1 : 1, v/v, 1 ml) and left overnight at room
temperature. Then the beads were washed with water
and 0.1 M EDTA solution. The cleavage and depro-
tection of CPG-bound oligonucleotide were performed
with aq. NH4OH/MeNH2 solution (1 :1, v/v, 1 ml) for
5 min at 65 °C. The resin was removed by filtration,
washed with H2O and the solution was evaporated
under reduced pressure. The residue was subsequently
heated with a solution of triethylamine trihydrofluor-
ide (125 μl) in DMSO (50 μl) at 65 °C for 1.5 h. Upon
cooling in an ice bath, AcONa (3 M, 25 μl) and BuOH
(1 ml) were added. The resulting suspension was
vortexed and cooled in a freezer (  80 °C) for 1 h. After
the centrifugation, supernatant was removed, and the
remaining oligonucleotide pellet was dried under
vacuum. The oligonucleotide was analyzed and puri-
fied using RP-HPLC. The structural integrity of RNA was
analyzed by MALDI-TOF mass measurement.
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